A two-part mixture model for longitudinal adverse event severity data

被引:29
作者
Kowalski, KG
McFadyen, L
Hutmacher, MM
Frame, B
Miller, R
机构
[1] Pfizer Global Res & Dev, Ann Arbor, MI 48105 USA
[2] Pfizer Ltd, Clin Sci IPC 746, Sandwich CT13 9NJ, Kent, England
[3] Pfizer Global Res & Dev, Skokie, IL 60077 USA
关键词
adverse events; nonlinear mixed effects modeling; empirical Bayes predictions; mixture model; model misspecification; NONMEM;
D O I
10.1023/B:JOPA.0000008157.26321.3c
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We fit a mixed effects logistic regression model to longitudinal adverse event (AE) severity data (four-point ordered categorical response) to describe the dose-AE severity response for an investigational drug. The distribution of the predicted interindividual random effects (Bayes predictions) was extremely bimodal. This extreme bimodality indicated that biased parameter estimates and poor predictive performance were likely. The distribution's primary mode was composed of patients that did not experience an AE. Moreover, the Bayes predictions of these non-AE patients were nearly degenerative; i.e., the predictions were nearly identical. To resolve this extreme bimodality we propose using a two-part mixture modeling approach. The first part models the incidence of AE's, and the second part models the severity grade given the patient had an AE. Unconditional probability predictions are calculated by mixing the incidence and severity model probability predictions. We also report results of simulation studies, which assess the predictive and statistical (bias and precision) performance of our approach.
引用
收藏
页码:315 / 336
页数:22
相关论文
共 16 条
[1]  
BEAL SL, 1992, NONMEM USERS GUIDES
[2]   Maximum likelihood methods for cure rate models with missing covariates [J].
Chen, MH ;
Ibrahim, JG .
BIOMETRICS, 2001, 57 (01) :43-52
[3]   THE USE OF MIXTURE-MODELS FOR THE ANALYSIS OF SURVIVAL-DATA WITH LONG-TERM SURVIVORS [J].
FAREWELL, VT .
BIOMETRICS, 1982, 38 (04) :1041-1046
[4]   Determination of an optimal dosage regimen using a Bayesian decision analysis of efficacy and adverse effect data [J].
Graham, G ;
Gupta, S ;
Aarons, L .
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2002, 29 (01) :67-88
[5]   Quantitative characterization of therapeutic index: Application of mixed-effects modeling to evaluate oxybutynin dose-efficacy and dose-side effect relationships [J].
Gupta, SK ;
Sathyan, G ;
Lindemulder, EA ;
Ho, PL ;
Sheiner, LB ;
Aarons, L .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (06) :672-684
[6]   ZERO-ALTERED AND OTHER REGRESSION-MODELS FOR COUNT DATA WITH ADDED ZEROS [J].
HEILBRON, DC .
BIOMETRICAL JOURNAL, 1994, 36 (05) :531-547
[7]  
HOGG RV, 1978, INTRO MATH STAT, P183
[8]   Efficient screening of covariates in population models using Wald's approximation to the likelihood ratio test [J].
Kowalski, KG ;
Hutmacher, MM .
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2001, 28 (03) :253-275
[9]   ZERO-INFLATED POISSON REGRESSION, WITH AN APPLICATION TO DEFECTS IN MANUFACTURING [J].
LAMBERT, D .
TECHNOMETRICS, 1992, 34 (01) :1-14
[10]   MODELING THE DROP-OUT MECHANISM IN REPEATED-MEASURES STUDIES [J].
LITTLE, RJA .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1995, 90 (431) :1112-1121